Watchman vs. Blood Thinners: Alternatives for Patients with Nonvalvular Atrial Fibrillation

New implant technology designed to thwart stroke shows promise for patients with atrial fibrillation who cannot take anticoagulants. Here’s what potential recipients need to know.

7:00 AM

Author | Kevin Joy

Watchman Implant or Blood Thinners for Nonvalvular Atrial Fibrillation

Patients with nonvalvular atrial fibrillation (Afib), the most common type of abnormal heart rhythm, are at increased risk of stroke and may need a blood-thinning anticoagulant to reduce the risk. However, some patients who need blood thinners may not be able to take them because of a high risk of life-threatening bleeding.

MORE FROM MICHIGAN: Sign up for our weekly newsletter

For such patients with nonvalvular atrial fibrillation who also are at high risk for severe bleeding complications, a quarter-sized device known as the Watchman might be a viable alternative. The tool blocks off a section of the heart commonly linked to blood clots, preventing any clots from escaping into the bloodstream.

"This is certainly something that can and should be considered in carefully evaluated, appropriate patients with nonvalvular Afib who need an anticoagulant but also are at high risk for severe bleeding complications," says Hakan Oral, M.D., a cardiologist at Michigan Medicine's Frankel Cardiovascular Center.

Available internationally since 2009, the Watchman has been approved since 2015 by the Food and Drug Administration. The Frankel center is one of the first facilities in the United States to use the device.

How the Watchman works

The lightweight, umbrella- or parachute-shaped device is inserted by catheter through a recipient's blood vessel accessed through the groin. It is designed to seal off the heart's left atrial appendage (a sacklike pouch within one of the organ's two upper chambers; the left atrial appendage is where Afib patients most often develop blood clots). A person's heart tissue will grow over the permanent implant in time.

The devices are available in several sizes to best fit a recipient's body.

Prior studies demonstrated that the Watchman was noninferior to the blood thinner warfarin, leading to FDA approval.  

But, as the FDA notes in a Watchman information guide, the device targets only one potential source of trouble. It cannot thwart other causes of stroke such as high blood pressure or narrowing of blood vessels to the brain.

Eligible candidates

The Watchman isn't meant to be a universal alternative to anticoagulants. Only carefully chosen patients should receive it, Oral says. "If a patient has a high risk of bleeding while on blood thinners, then it is a very good option."

SEE ALSO: Clearing Up Confusion About Blood-Thinning Meds

Still, patients must be able to tolerate warfarin short term to qualify. A patient must also be at an increased risk for stroke and systemic embolism based on CHADS2 or CHA2DS2-VASc scores — numerical scales used to evaluate stroke risk in Afib patients.

A potential recipient will undergo a transesophageal echocardiogram (TEE) to ensure no existing clots are present and to determine whether the appendage is compatible with one of the available device sizes and shapes. Clots, if detected, will need to be treated with blood thinners before proceeding.

The Centers for Medicare and Medicaid Services announced in February 2016 that the Watchman will be covered, as long as patients meet specific criteria.

Living with the Watchman

Conducted under general anesthesia, the minimally invasive procedure doesn't typically involve a hospital stay of more than a day. Patients should be able to return to normal activities shortly after the procedure.

Extended follow-up, though, is involved. A recipient can expect subsequent TEEs at 45 days and 12 months after surgery to ensure that the Watchman is working properly and the left atrial appendage remains closed.

Patients also need to continue a warfarin regimen for 45 days.

"After a successful implant confirmed at 45 days with a TEE, the patient is taken off warfarin and put on a different type of blood thinner known as Plavix, along with aspirin, for another four and one-half months," Oral says. "The patient is then maintained on aspirin for life."

Like any other procedure, Oral says, the Watchman device has its own risks. "Therefore, patients must be carefully chosen."

Want to know which option is right for you? Call the Frankel Cardiovascular Center at 888-287-1082 for more information or to make an appointment.

More Articles About: Heart Health Atrial fibrillation (Afib) Frankel Cardiovascular Center Emerging Technologies Cardiovascular: Diseases & Conditions
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of healthcare news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]


Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Featured News & Stories person in white coat at laptop green fruit in hand
Health Lab
Both virtual and in-person nutrition visits help to lower cholesterol
The use of telehealth remains high, with over 20% of American adults taking appointments online. These visits include video calls with registered dietitian nutritionists, who have a critical role in helping patients take on lifestyle changes through medical nutrition therapy. With a focus on the changing digital landscape, researchers at Michigan Medicine found that telemedicine patients with hyperlipidemia — an excess of cholesterol or fats in the blood — experienced similar positive health benefits compared to those who had in-person visits.
smart watch on wrist
Health Lab
Clinical smart watch finds success at identifying atrial fibrillation
A Michigan Medicine research team developed a prescription wristwatch that continuously monitors the wearer’s heart rhythm and uses a unique algorithm to detect atrial fibrillation. The clinical-grade device, called the Verily Study Watch, proved very accurate at identifying atrial fibrillation in participants.
supar molecule teal blue yellow red
Health Lab
Immune protein suPAR links viral infection as possible cause of kidney disease
Through a series of experiments in non-human primates, mice and humans, a multi-institutional team led by researchers from Michigan Medicine and Rush University found that the immune protein soluble urokinase plasminogen activator receptor, or suPAR, is an important link between viral infections and proteinuria; the elevation of protein in the urine is known to cause glomerulopathy, a common form of kidney disease.
expert at stand hearing in suit
Health Lab
Keep telehealth alive and well, experts tell Senate subcommittee
Telehealth coverage by Medicare is scheduled to expire at the end of 2024; experts told Senators what they think should happen to preserve it.
man in scrubs sitting with scrub cap with headset on in clinical setting
Health Lab
Medical students use virtual reality to improve diabetes
A physician invents a creative approach for medical students in diabetic care.
heart organ yellow blue
Health Lab
Irregular heartbeat after valve surgery increases risk of stroke, death
Postoperative atrial fibrillation, commonly known as Afib, has traditionally been viewed as benign and limited. But a study led by researchers at the University of Michigan Health Frankel Cardiovascular Center finds that postoperative atrial fibrillation increases the risk of strokes and permanent Afib — and is linked to worse long term survival — after heart valve surgery.